Age-related macular degeneration (AMD) is responsible for approx. 9% of the world's blindness, affecting 2 million people in the United States. Pathological neovasculation is one of the main causes of degeneration of the central vision region of the retina. VEGF and its receptors, VEGFR and co-receptor Neuropilin (Nrp) together with plexins, direct this formation of blood vessels, but the receptors also regulate cell survival and proliferation. Over the last decade, anti-VEGF therapy has become a principal mode of treatment for AMD. Several antibodies against VEGF-A, Ranibizumab and off-label use of Bevacizumab, are effective in slowing visual loss in 90% of patients. However, their long term effects on angiogenesis are not yet known and resistance against VEGFR blockade-like treatments has already become a problem. Thus a deeper understanding of Neuropilin/VEGFR/Plexin signaling is needed at the molecular level for the design of more specific agents. Furthermore, both drugs need to be injected directly into the eye every month, making the development of therapeutics that can be administered at least intravenously, if not orally, highly desirable. The proposed project focuses on Neuropilin signaling at the molecular and mechanistic level. As yet there is no detailed structural information for the transmembrane (TM) segment, for the well conserved 46 residues just outside the cell, or for the 44 residue intracellular region of Nrp1. We hypothesize that the relationship between the TM and membrane proximal regions constitutes key parts of the mechanism for transmembrane signaling;specifically the regions are likely to participate in regulatory events in a hierarchical manner. Peptides corresponding to the Nrp1 TM region can inhibit receptor function and angiogenesis. However, insights are needed at the molecular level in order to understand this mechanism and to optimize the peptide inhibitors, utilizing the context of the membrane surrounding regions, for anti- angiogenesis therapy. Our structural studies will synergize with functional studies of Nrp1 that are ongoing in several laboratories.
Age-related macular degeneration (ADM) is responsible for approx. 9% of the world's blindness and is affecting 2 million people in the United States. It is a common, chronic and progressive degeneration of vision in the center of the visual field (macula) that in a large part is due to pathological formation of new blood vessels. These vessels lead to a disruption and swelling of the eyes'retina. Over the last few years, administration of antibodies that block a protein involved in blood vessel formation has become a principal mode of treatment. What effects these therapeutics have on normal blood vessel development over the longer term (on the order of decades) is not yet understood and the retina cells may become resistant against a single agent treatment. Furthermore, the current drugs need to be injected directly into the eye every month. Thus, agents should be developed that can be administered orally, as eye drops or at least intravenously. The proposed pilot project will lay the groundwork to further develop an additional/alternative therapeutic. One such agent is a peptide inhibitor against another protein, neuropilin-1, that is also involved in blood vessel development and has already shown promise in a preclinical setting. Basic knowledge of this important system is missing at the molecular level, especially of the neuropilin1 regions in and near the cellular membrane. The interactions of these regions also with co-receptors are not yet characterized. For the first time the structural details of the trans membrane and membrane nearby regions of neuropilin-1 will be studied, both in isolation and when they are joined together. Utilizing a combined experimental and computational approach, the derived knowledge will allow the further development of therapeutic peptide agents.
|Zhang, Liqun; Polyansky, Anton; Buck, Matthias (2015) Modeling transmembrane domain dimers/trimers of plexin receptors: implications for mechanisms of signal transmission across the membrane. PLoS One 10:e0121513|